Nova Eye (Australia) Performance
| EYE Stock | 0.15 0.01 7.14% |
The company secures a Beta (Market Risk) of -0.29, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Nova Eye are expected to decrease at a much lower rate. During the bear market, Nova Eye is likely to outperform the market. At this point, Nova Eye Medical has a negative expected return of -0.52%. Please make sure to verify Nova Eye's maximum drawdown, skewness, accumulation distribution, as well as the relationship between the potential upside and kurtosis , to decide if Nova Eye Medical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nova Eye Medical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:5 | Ex Dividend Date 2020-07-21 | Last Split Date 2001-07-10 |
1 | When Will Nova Eye Medical Limited Become Profitable - Simply Wall St | 09/10/2024 |
2 | Nova Eye Medical Schedules AGM and Director Elections - TipRanks | 09/26/2024 |
3 | Nova Eye Medical Discusses Future Expectations and Risks - TipRanks | 11/20/2024 |
| Begin Period Cash Flow | 7.4 M | |
| Free Cash Flow | -8.3 M |
Nova |
Nova Eye Relative Risk vs. Return Landscape
If you would invest 21.00 in Nova Eye Medical on August 28, 2024 and sell it today you would lose (7.00) from holding Nova Eye Medical or give up 33.33% of portfolio value over 90 days. Nova Eye Medical is producing return of less than zero assuming 4.6534% volatility of returns over the 90 days investment horizon. Simply put, 41% of all stocks have less volatile historical return distribution than Nova Eye, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Nova Eye Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nova Eye's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nova Eye Medical, and traders can use it to determine the average amount a Nova Eye's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1108
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EYE |
Estimated Market Risk
| 4.65 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.52 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nova Eye is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nova Eye by adding Nova Eye to a well-diversified portfolio.
Nova Eye Fundamentals Growth
Nova Stock prices reflect investors' perceptions of the future prospects and financial health of Nova Eye, and Nova Eye fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nova Stock performance.
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 30.41 M | ||||
| Shares Outstanding | 229.06 M | ||||
| Price To Book | 1.56 X | ||||
| Price To Sales | 1.52 X | ||||
| Revenue | 23.32 M | ||||
| Gross Profit | 14.39 M | ||||
| EBITDA | (5.98 M) | ||||
| Net Income | (8.79 M) | ||||
| Cash And Equivalents | 7.42 M | ||||
| Total Debt | 3.35 M | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (7.86 M) | ||||
| Earnings Per Share | (0.04) X | ||||
| Total Asset | 29.88 M | ||||
| Retained Earnings | (30.69 M) | ||||
About Nova Eye Performance
Assessing Nova Eye's fundamental ratios provides investors with valuable insights into Nova Eye's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Nova Eye is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Nova Eye is entity of Australia. It is traded as Stock on AU exchange.Things to note about Nova Eye Medical performance evaluation
Checking the ongoing alerts about Nova Eye for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nova Eye Medical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nova Eye Medical generated a negative expected return over the last 90 days | |
| Nova Eye Medical has some characteristics of a very speculative penny stock | |
| Nova Eye Medical has high historical volatility and very poor performance | |
| The company reported the revenue of 23.32 M. Net Loss for the year was (8.79 M) with profit before overhead, payroll, taxes, and interest of 14.39 M. | |
| Nova Eye Medical has accumulated about 7.42 M in cash with (7.86 M) of positive cash flow from operations. | |
| Roughly 19.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Nova Eye Medical Discusses Future Expectations and Risks - TipRanks |
- Analyzing Nova Eye's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nova Eye's stock is overvalued or undervalued compared to its peers.
- Examining Nova Eye's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nova Eye's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nova Eye's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nova Eye's stock. These opinions can provide insight into Nova Eye's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nova Stock Analysis
When running Nova Eye's price analysis, check to measure Nova Eye's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Eye is operating at the current time. Most of Nova Eye's value examination focuses on studying past and present price action to predict the probability of Nova Eye's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Eye's price. Additionally, you may evaluate how the addition of Nova Eye to your portfolios can decrease your overall portfolio volatility.